Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene

Bashir, Amani; Mak, Y. T.; Sankaralingam, S; Cheung, J; McGowan, Neil; Grigoriadis, Anita; Fogelman, Ignac; Hampson, Geeta

doi:10.1016/j.steroids.2005.04.011

Cited by 38 publications

(17 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, similarly as in our results, the authors of the study obtained positive values of sRANKL only in a small group of patients; in all the other cases sRANKL values were below assayable level [35].…”

Section: Prace Oryginalnesupporting

confidence: 89%

“…Analysing the effects of antiresorptive medications, it is also worth mentioning the results of the study by Bashir et al [35], who evaluated the influence of 12-month hormonal replacement therapy (HRT) with administration of raloxifene to female patients with postmenopausal osteoporosis. They demonstrated a significant drop of expression of all the three elements of the OPG/RANK/RANKL system, after just six months of using both therapy forms and a significant decrease of OPG concentration in serum after just one month of treatment, and that tendency was maintained until the end of the study.…”

Section: Prace Oryginalnementioning

confidence: 99%

See 1 more Smart Citation

Ocena stężeń OPG, RANKL i markerów obrotu kostnego w surowicy oraz BMD u pacjentek leczonych z powodu osteoporozy pomenopauzalnej ranelinianem strontu i ibandronianem

Stuss

Sewerynek

Król

et al. 2016

Endokrynologia Polska

View full text Add to dashboard Cite

Section: Prace Oryginalnesupporting

confidence: 89%

Section: Prace Oryginalnementioning

confidence: 99%

Ocena stężeń OPG, RANKL i markerów obrotu kostnego w surowicy oraz BMD u pacjentek leczonych z powodu osteoporozy pomenopauzalnej ranelinianem strontu i ibandronianem

Stuss

Sewerynek

Król

et al. 2016

Endokrynologia Polska

View full text Add to dashboard Cite

“…OPG acts as a decoy receptor of osteoblast and stromal cell -produced RANKL and contributes to previously been demonstrated to increase osteoblastic OPG mRNA and protein levels in a dose dependent way (Saika et al, 2001, Lindberg et al, 2001, Bord et al, 2003Hofbauer et al, 1999 Not just OPG, but also RANKL and the ratio of RANKL/OPG are important in the modulation of bone homeostasis by estrogen (Bord et al, 2003;Bashir et al, 2005).…”

mentioning

confidence: 97%

Estrogen and the selective estrogen receptor modulator (SERM) protection against cell death in estrogen receptor alpha and beta expressing U2OS cells

Kallio

Guo

Lamminen

et al. 2008

Molecular and Cellular Endocrinology

View full text Add to dashboard Cite

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Transfection with either of the ERs was able to render the U2OS cells sensitive to E 2 . Weshow that E 2 opposed etoposide-induced apoptosis and that the effect was mediated via both ER isotypes. The ER isotype selective agonists propyl-pyrazole-triol (PPT) and diarylpropionitrile (DPN) had the same effect in U2OS/ERα and U2OS/ER cells, respectively. Osp also opposed apoptosis at least in U2OS/ERα cells. Tam and Ral were not able to protect against etoposide-induced cell death. In order to evaluate the protective effects of E 2 and Osp upon etoposide challenge we studied the expression of two E 2 -regulated, osteoblast-produced cytokines, IL-6 and OPG in E 2 and SERM-treated U2OS/ERα and U2OS/ER cells. Etoposide strongly increased expression of IL-6 and decreased that of OPG.E 2 opposed IL-6 increase only in U2OS/ERα cells and OPG decrease primarily in ER cells.Osp opposed the effect of etoposide on OPG primarily in U2OS/ER cells but interestingly, it had little effect on IL-6 expression. E2, PPT, DNP and Osp also inhibited etoposideinduced death and cytokine changes in SAOS-2 osteosarcoma cells expressing endogenous ERα and ER. Collectively, our results suggest that the osteoblast protective antiapoptotic effects of E 2 are mediated by both ERα and ER but those of Osp primarily by ER. In addition, E 2 and Osp opposed the etoposide-induced increase of IL-6 and decrease of OPG which changes would increase osteoclastic activity. These antiresorptive effects of E 2 andPage 3 of 53 A c c e p t e d M a n u s c r i p t 2 Osp upon etoposide challenge differed from each other and they seemed to be differentially mediated in ERα and ER expressing osteoblast-derived U2OS cells.

show abstract

“…It has been shown previously that raloxifene influences TNFSF11 and TNFRSF11B expression in peripheral blood mononuclear cells [9] possibly through estrogen, ERα, and estrogen response element-binding proteins [10]. Additionally, regarding the +34694C > T SNP of TNFRSF11A, the CTX concentration decreased to a greater extent in women carrying CC genotype, indicating their better response to raloxifene therapy.…”

Section: Discussionmentioning

confidence: 77%

Raloxifene pharmacodynamics is influenced by genetic variants in the RANKL/RANK/OPG system and in the Wnt signaling pathway

Mencej-Bedrač

Zupan

Mlakar

et al. 2014

Drug Metabolism and Drug Interactions

View full text Add to dashboard Cite

We have shown that, in postmenopausal osteoporotic women treated with raloxifene, the efficacy of raloxifene treatment might be influenced by +34901G>A in TNFRSF11A gene and -1397_-1396insGGA in the SOST gene as well as -643C>T in TNFSF11 gene and +34694C>T in TNFRSF11A gene. However, these findings need additional functional and clinical confirmation for potential pharmacogenetic use in the future.

show abstract

Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene

Cited by 38 publications

References 31 publications

Ocena stężeń OPG, RANKL i markerów obrotu kostnego w surowicy oraz BMD u pacjentek leczonych z powodu osteoporozy pomenopauzalnej ranelinianem strontu i ibandronianem

Ocena stężeń OPG, RANKL i markerów obrotu kostnego w surowicy oraz BMD u pacjentek leczonych z powodu osteoporozy pomenopauzalnej ranelinianem strontu i ibandronianem

Estrogen and the selective estrogen receptor modulator (SERM) protection against cell death in estrogen receptor alpha and beta expressing U2OS cells

Raloxifene pharmacodynamics is influenced by genetic variants in the RANKL/RANK/OPG system and in the Wnt signaling pathway

Contact Info

Product

Resources

About